Systemic Sclerosis-associated Interstitial Lung Disease Market Expected to rise, 2034 | Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche

The Systemic Sclerosis-associated Interstitial Lung Disease market growth is driven by factors like increase in the prevalence of Systemic Sclerosis-associated Interstitial Lung Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Systemic Sclerosis-associated Interstitial Lung Disease market report [https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Systemic Sclerosis-associated Interstitial Lung Disease market size, share, Systemic Sclerosis-associated Interstitial Lung Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Systemic Sclerosis-associated Interstitial Lung Disease market size growth forward.

Some of the key highlights from the Systemic Sclerosis-associated Interstitial Lung Disease Market Insights Report:

*
Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Systemic Sclerosis-associated Interstitial Lung Disease treatment outlook.

*
In November 2024, aTyr Pharma, Inc. announced the ongoing enrollment of patients in the Phase 2 EFZO-CONNECT Trademark trial, designed to evaluate the efficacy, safety, and tolerability of efzofitimod in individuals with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This 28-week, randomized, double-blind, placebo-controlled study consists of three parallel cohorts. Participants are assigned in a 2:2:1 ratio to receive either 270 mg or 450 mg of efzofitimod, or a placebo, administered intravenously once a month for a total of six doses. The trial aims to enroll up to 25 SSc-ILD patients and is actively recruiting at multiple sites across the U.S.

*
The market for Systemic Sclerosis-associated Lung Disease is expected to experience significant growth, driven by increased adoption of existing treatments, the anticipated introduction of one-time gene therapies, and heightened awareness.

*
Systemic Sclerosis (SSc) is a condition marked by fibrosis, vasculopathy, and inflammation, affecting multiple organs and systems with serious prognostic implications. When SSc impacts the lungs, it can lead to pulmonary complications such as interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH).

*
Patients with SSc face a high risk of developing ILD as a complication, which can result in lung inflammation and scarring, ultimately leading to respiratory failure.

*
Among global markets, the United States holds the largest share of the Systemic Sclerosis-associated Lung Disease market, surpassing the EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan.

*
The higher prevalence of SSc-ILD in females in the U.S. is attributed to the increased occurrence of systemic sclerosis in women, likely influenced by genetic and hormonal factors.

*
Severity-specific data indicates that moderate cases of SSc-ILD are significantly more common than severe cases.

*
As per DelveInsight analysis, the Systemic Sclerosis-associated Interstitial Lung Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Systemic Sclerosis-associated Interstitial Lung Disease Market Landscape [https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Systemic Sclerosis-associated Interstitial Lung Disease Overview

Systemic Sclerosis (SSc) is a condition marked by fibrosis, vasculopathy, and inflammation, affecting multiple organs. When the lungs are involved, it can lead to interstitial lung disease (ILD) and/or pulmonary arterial hypertension (PAH). Although the exact cause of SSc-ILD remains uncertain, a combination of environmental, immune, and genetic factors is believed to play a role. Patients with SSc are highly susceptible to developing ILD, which may cause lung inflammation and scarring, ultimately leading to respiratory failure.

Diagnosing Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) primarily involves identifying ILD on high-resolution computed tomography (HRCT) scans of the chest in individuals with known SSc while excluding other potential causes of lung disease. A thorough clinical assessment, including an evaluation of respiratory symptoms, is essential for all newly diagnosed SSc patients to detect lung involvement as early as possible. Early identification is critical, as ILD significantly contributes to both morbidity and mortality in this patient population.

Do you know the treatment paradigms for different countries? Download our Systemic Sclerosis-associated Interstitial Lung Disease Market Sample Report [https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Insights

*
According to DelveInsight's analysis, in 2023, the highest prevalence of diagnosed SSc-ILD cases was observed in individuals aged 65 and older, while the lowest was recorded in the 0-18 age group.

*
Additionally, in the U.S., the majority of diagnosed prevalent SSc-ILD cases were classified as being in the moderate severity stage.

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology Segmentation

DelveInsight's Systemic Sclerosis-associated Interstitial Lung Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Systemic Sclerosis-associated Interstitial Lung Disease historical patient pools and forecasted Systemic Sclerosis-associated Interstitial Lung Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Systemic Sclerosis-associated Interstitial Lung Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Systemic Sclerosis-associated Interstitial Lung Disease Prevalence

*
Age-Specific Systemic Sclerosis-associated Interstitial Lung Disease Prevalence

*
Gender-Specific Systemic Sclerosis-associated Interstitial Lung Disease Prevalence

*
Diagnosed and Treatable Cases of Systemic Sclerosis-associated Interstitial Lung Disease

Visit for more @ Systemic Sclerosis-associated Interstitial Lung Disease Epidemiological Insights [https://www.delveinsight.com/sample-request/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Systemic Sclerosis-associated Interstitial Lung Disease Market Outlook

Leading companies such as Prometheus Biosciences, Genentech, GlaxoSmithKline, Merck & Co., and others are actively advancing their key drug candidates through various stages of clinical development. Their goal is to evaluate these therapies for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD).

The current pipeline for Systemic Sclerosis-associated Lung Disease includes promising drug candidates such as PRA023, belimumab (GSK1550188), and vixarelimab (KPL-716), among others.

Among the EU4 countries and the UK, the United Kingdom held the largest market share for Systemic Sclerosis-associated Lung Disease in 2023.

Systemic Sclerosis associated Lung Disease Marketed Drugs

*
ACTEMRA/ROACTEMRA (tocilizumab): Roche

*
OFEV (nintedanib): Boehringer Ingelheim

Systemic Sclerosis associated Lung Disease Emerging Drugs

*
GSK1550188/Belimumab (BENLYSTA): GlaxoSmithKline

*
PRA023: Merck

Systemic Sclerosis-associated Interstitial Lung Disease Key Companies

*
Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others

For more information, visit Systemic Sclerosis-associated Interstitial Lung Disease Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Systemic Sclerosis-associated Interstitial Lung Disease Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Systemic Sclerosis-associated Interstitial Lung Disease, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Systemic Sclerosis-associated Interstitial Lung Disease epidemiology in the 7MM

*
Systemic Sclerosis-associated Interstitial Lung Disease marketed and emerging therapies

*
Systemic Sclerosis-associated Interstitial Lung Disease companies

*
Systemic Sclerosis-associated Interstitial Lung Disease market drivers and barriers

Table of Contents:

1 Systemic Sclerosis-associated Interstitial Lung Disease Market Key Comprehensive Insights

2 Systemic Sclerosis-associated Interstitial Lung Disease Market Report Introduction

3 Competitive Intelligence Analysis for Systemic Sclerosis-associated Interstitial Lung Disease

4 Systemic Sclerosis-associated Interstitial Lung Disease Market Analysis Overview at a Glance

5 Executive Summary of Systemic Sclerosis-associated Interstitial Lung Disease

6 Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Market Methodology

7 Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology and Patient Population

8 Systemic Sclerosis-associated Interstitial Lung Disease Patient Journey

9 Systemic Sclerosis-associated Interstitial Lung Disease Treatment Algorithm, Systemic Sclerosis-associated Interstitial Lung Disease Current Treatment, and Medical Practices

10 Key Endpoints in Systemic Sclerosis-associated Interstitial Lung Disease Clinical Trials

11 Systemic Sclerosis-associated Interstitial Lung Disease Marketed Therapies

12 Systemic Sclerosis-associated Interstitial Lung Disease Emerging Therapies

13 Systemic Sclerosis-associated Interstitial Lung Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Systemic Sclerosis-associated Interstitial Lung Disease

16 Systemic Sclerosis-associated Interstitial Lung Disease Market Key Opinion Leaders Reviews

18 Systemic Sclerosis-associated Interstitial Lung Disease Market Drivers

19 Systemic Sclerosis-associated Interstitial Lung Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Systemic Sclerosis-associated Interstitial Lung Disease Epidemiology 2034

DelveInsight's "Systemic Sclerosis-associated Interstitial Lung Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Systemic Sclerosis-associated Interstitial Lung Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Systemic Sclerosis-associated Interstitial Lung Disease Pipeline 2024

"Systemic Sclerosis-associated Interstitial Lung Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Systemic Sclerosis-associated Interstitial Lung Disease market. A detailed picture of the Systemic Sclerosis-associated Interstitial Lung Disease pipeline landscape is provided, which includes the disease overview and Systemic Sclerosis-associated Interstitial Lung Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-sclerosisassociated-interstitial-lung-disease-market-expected-to-rise-2034-bristol-myers-squibb-company-merck-and-co-inc-mylan-pharmaceutical-ltd-novartis-ag-pfizer-inc-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.